

Amendment to the Claims:

Claims 1-62 (Canceled)

63. (Currently amended) A transgenic mouse whose genome comprises a null endogenous lymphoid specific GPCR allele; ~~wherein said null allele comprises exogenous DNA, said exogenous DNA comprising a gene encoding a visible marker, wherein said gene is capable of expression in the spleen.~~
64. (Previously presented) The transgenic mouse of claim 63, wherein the mouse is homozygous for said null allele.
65. (Previously presented) The transgenic mouse of claim 64, wherein the mouse exhibits, relative to a wild-control mouse, lymphocyte cellular infiltration of liver tissue and/or pancreatic tissue.
66. (Previously presented) The transgenic mouse of claim 64, wherein the mouse exhibits, relative to a wild-type control mouse, cellular infiltration of stomach tissue by at least one of the following types of cells: lymphocytes, granulocytes or plasma cells.
67. (Previously presented) A cell or tissue isolated from the transgenic mouse of claim 63.
68. (Previously presented) The transgenic mouse of claim 63, wherein the mouse is heterozygous for said null allele.
69. (Previously presented) A cell or tissue isolated from the transgenic mouse of claim 68.
70. (Previously presented) A method of producing a transgenic mouse of claim 63, the method comprising:
- (a) introducing a targeting construct capable of disrupting the endogenous lymphoid specific GPCR gene into a murine embryonic stem cell;
 - (b) selecting for the murine embryonic stem cell that has undergone homologous recombination;
 - (c) introducing the murine embryonic stem cell selected for in step (b) into a mouse blastocyst;
 - (d) implanting the resulting blastocyst into a pseudopregnant mouse, wherein the resultant mouse gives birth to a chimeric mouse; and
 - (e) breeding the chimeric mouse to produce the transgenic mouse.
71. (Canceled)

72. (Currently amended) The transgenic mouse of claim 63 wherein said ~~exogenous DNA~~null allele ~~further~~ comprises a gene encoding a selection marker.
73. (Previously presented) The transgenic mouse of claim 72 wherein said gene is a neomycin resistant gene.
74. (Currently amended) The transgenic mouse of claim ~~63~~73 wherein said null allele further comprises a~~gene is~~lacZ gene.
75. (Currently amended) The transgenic mouse of claim ~~63~~74 wherein said lacZ gene is capable of expression in the spleen and lymph nodes.
76. (Currently amended) A method of identifying an agent capable of modulating activity of a lymphoid specific GPCR gene or lymphoid specific GPCR gene expression product, the method comprising:
- (a) administering a putative agent to the transgenic mouse of claim ~~46~~63;
 - (b) administering the agent to a wild-type control mouse; and
 - (c) comparing a physiological response of the transgenic mouse with that of the control mouse;
 - (d) wherein a difference in the physiological response between the transgenic mouse and the control mouse is an indication that the agent is capable of modulating activity of the gene or gene expression product.